BioInteractions, a leading UK biomaterial technology company, has launched a new Surface Active Therapeutic coating for medical devices: AstutePlus. AstutePlus is an advanced antithrombogenic designed specifically to stop fibrin sheath formation as well as thrombus formation in blood-contacting devices.

The company says that this is a significant challenge for physicians using central veinous catheters (CVCs), as it affects the safety and effectiveness of treatments like hemodialysis. BioInteractions will be exhibiting at COMPAMED 2024 on November 11-14 2024 showcasing AstutePlus alongside its other coating solutions.   

Fibrin sheath formation is a common challenge for clinicians using CVCs for hemodialysis and other blood-contacting therapies. When a catheter is placed in the bloodstream, the body can react by forming a thrombus and fibrous layer around it, blocking blood flow and making the device less effective.